http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8535672-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a422c563d66137a2265e7af4c47a7b54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1f8b0dde05f627ff30b3bb16c87ca155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_18deaaf6d7efc32a7dad5812dd7eacc6 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70521 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate | 2004-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9344340eb2d9082cce8dff0c6b5d86da http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f275c8b8715f09e8112369f829faf90e |
| publicationDate | 2013-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-8535672-B2 |
| titleOfInvention | Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between CD28 and the superantigen and uses thereof |
| abstract | Disclosed are methods and compositions for the inhibition of modulation of T cell costimulatory pathway by a pathogenic agent, particularly, the inhibition of activation of a T cell costimulatory pathway, preferably, the CD28/B7 pathway, by a pyrogenic exotoxin. The method of the invention is based on the inhibition of the direct interaction of a superantigen with a specific site within the dimer interface of a CD28 family member, using immunomodulatory peptides. Further disclosed are specific antagonist immunomodulatory peptides comprising an amino acid sequence derived from a dimer interface of a T cell co-stimulatory pathway member, or peptides which comprise an amino acid sequence which specifically binds to an amino acid sequence within the dimer interface of a T cell co-stimulatory pathway member. Compositions comprising said peptides and methods for the treatment of immune-related disorders are also disclosed. n Also disclosed is the use of the CD28 molecule or any fragment thereof comprising the sAg binding site in a method of screening for a test substance which specifically binds to the CD28 molecule and is capable of antagonizing pyrogenic exotoxin-mediated activation of Th1 lymphocytes. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11344578-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016289295-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10280209-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9963497-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9920123-B2 |
| priorityDate | 2002-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 672.